Biocon Limited BIOCON
NSE · India · Health Technology
INR 370.70+0.40 (+0.11%)
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Biocon Biologics Limited, a wholly-owned subsidiary of Biocon Limited (BSE: 532523) (NSE: BIOCON), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the granting of a marketing authorisation to its Pertuzumab biosimilar as 420 mg concentrate solution for infusion, under the brand name Pebrilzo®, for the treatment of HER2–positive breast cancer across multiple disease stages.
Biocon’s updated analyst model now points to a fair value of ₹446.89, compared with the earlier estimate of ₹429.67, which translates to a roughly 4% uplift in the price target. Recent analyst commentary links this higher fair value to views on Biocon’s execution quality, earnings visibility, and how the current risk profile compares with that new target. As you read on, you will see how this revised price target fits into the evolving narrative around the stock and what it may mean for your...
Tariff threats from the US are colliding with India’s export surge, and that clash is putting a fresh spotlight on large-cap exporters with heavy US exposure. Some stocks could see pressure if trade friction bites. Others may benefit as supply chains and free trade deals are rewired. This article breaks down three such stocks from the screener and how this news could matter for your portfolio decisions. The three stocks covered below are just a sample from this theme, and the full screen...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.